| Peer-Reviewed

Late Primary B Cell Cerebral Lymphoma After Kidney Transplant: A Case Report and Literature Review

Received: 16 May 2021     Accepted: 31 May 2021     Published: 2 August 2021
Views:       Downloads:
Abstract

Background: Primary central nervous system post-transplant lymphoproliferative disorder (PCNS-PTLD) is a serious and uncommon complication which can be developed months or years after a Kidney transplant. Immunosuppressive agents administered before and after transplantation to minimize the chances of allograft rejection has proved to be a double-edged sword that puts the host at risk of infectious, neoplastic and vascular diseases, including PCNS-PTLD. The immunosuppressive therapy leads to decreased innate malignant and viral immune surveillance and this has been shown to play a role in lymphoproliferative diseases after transplantation. In most cases, PCNS-PTLD is Epstein–Barr virus related. Case Description: A 60-year-old female with history of kidney transplant presented to the emergency room with history of low fever, dizziness nausea and vomiting for 1 month. MRI and CT scans showed a mass cerebellar lesion and a biopsy revealed Primary central nervous system post-transplant lymphoproliferative disorder (PCNS-PTLD). Conclusion: This case highlights the need for a careful long-term follow up of patients with kidney transplant. PCNS-PTLD represents a continuing long-term risk after transplantation, although less common. This case report supports observational data that suggests that peripheral blood screening for EBV DNA does not seem helpful for identification of PCNS-PTLD. Suspicion of PCNS PTLD should be considered when patients with long-term history of kidney transplant present neurological complaints.

Published in Journal of Surgery (Volume 9, Issue 4)
DOI 10.11648/j.js.20210904.19
Page(s) 193-198
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

Central Nervous System, Primary B Cell Lymphoma, Transplantation, Kidney

References
[1] Bagg A., & Dunphy CH. (2013). Immunosuppressive and immunomodulatory therapy-associated lymphoproliferative disorders. Semin Diagn Pathol, 30: 102–12.
[2] Castellano-Sanchez AA., Li S., Qian J., Lagoo A., Weir E., & Brat DJ. (2004) Primary central nervous system posttransplant lymphoproliferative disorders. Am J Clin Pathol, 121: 246–253.
[3] Chou AP., Lalezari S., Fong BM., Dye J., Pham T., Vinters HV., & Pouratian N. (2011) Post-transplantation primary central nervous system lymphoma: A case report and review of the literature. Surg Neurol Int, 2: 130.
[4] Crane GM, Powell H, Kostadinov R, Rocafort PT, Rifkin DE, Burger PC., Ambinder RF., Swinnen L. J., Borowitz M. J., & Duffield A. S. (2015). Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget, 6: 33849–66.
[5] Degen D., Kanellis J., Hughes P., Barit D., & Francesco Lerino F. (2016). Primary central nervous system posttransplant lymphoproliferative disease: an uncommon diagnostic dilemma. Nephrology 21 (6): 528.
[6] Dierickx D., Tousseyn T., De Wolf-Peeters C., Pirenne J., & Verhoef G. (2011). Management of posttransplant lymphoproliferative disorders following solid organ transplant: an update. Leuk & Lymphoma 52: 950–961.
[7] Gavrilina O. A., Troitskaya V. V., Zvonkov E. E., Parovichnikova E. N., Galstyan G. M., Biryukova I. S., Nesterenko I. V., Kovrigina A. M., Bazhenov A. V., & Savchenko V. G. (2017). EBV-positive central nervous system lymphoproliferative disease associated with immunosuppression after organ transplantation: Long-term remission without chemotherapy. Ter Arkh, 89 (7): 69-75.
[8] Gerstner E. R., & Batchelor T. T. (2010). Primary central nervous system lymphoma. Arch Neurol 67: 291–297.
[9] González F., Gómez C., Cabrera M. E., Ayala A., & Roessler E. (1994). Primary cerebral lymphoma following kidney transplant: a case report and review of the literature. Rev Med Chil, 122 (11): 1294-7.
[10] Guglielmo N., Levi Sandri G. B., Melandro F., Garofalo M., Poli L., & Berloco P. (2015). Cerebral Lymphoma in a Kidney Transplant: A Case Report. Exp Clin Transplant, 13 (6): 600-2.
[11] Gutierrez-Dalmau A., & Campistol J. M. (2007). Immunosuppressive Therapy and Malignancy in Organ Transplant Recipients: A Systematic Review. Drugs. 67 (8): 1167-98.
[12] Hansen P. B., & Al-Farra G. (2010) Treatment of central nervous system lymphoma following transplantation using monoclonal antibody and ganciclovir. Ugeskr Laeger, 18; 172 (42): 2907-8. Danish.
[13] Haoliang X., Rewerska J., Aardsma N., Slavin K., Valyi-Nagy T., & Ni H. (2017) EBV-positive post-transplant lymphoproliferative disorder presenting as primary diffuse large B-cell lymphoma of the central nervous system. Folia Neuropathol, 55 (3): 221-226.
[14] Higuchi M., Hata T., Furuya S., Hosaka S., Kamijo Y., Kiyosawa K., Ishizuka O., Nishizawa O., & Hora K. (2005). Epstein-Barr virus-related primary central nervous system lymphoma after cadaveric renal transplantation improved by treatment with high-dose methotrexate followed by irradiation. Nephrology (Carlton). 10 (3): 321-4.
[15] Kempf C., Tinguely M., & Rushing E. J. (2013). Posttransplant Lymphoproliferative Disorder of the Central Nervous System. Pathobiology, 80: 310-318.
[16] Kutok J. L., & Wang F. (2006). Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol, 1: 375–404.
[17] Manez R., Breinig M. C., Linden P., Wilson J., Torre-Cisneros J., Kusne S., Dummer S., & Ho M., (1997). J Infect Dis. 176 (6): 1462-7.
[18] Morris J., Smith C., Streicher A., Magnuson A., Newman S., & Bertoli R. (2017). A Rare Presentation of Isolated CNS Post transplantation Lymphoproliferative Disorder. Case Reports in Oncological Medicine, Article ID 7269147, 5 pages.
[19] Nabors L. B., Palmer C. A., Julian B. A., Przekwas A. M., & Kew C. E. (2009). Isolated central nervous system posttransplant lymphoproliferative disorder treated with high-dose intravenous methotrexate. Am J Transplant. 9 (5): 1243-8.
[20] O’Neill B. P, Vernino S., Dogan A., & Giannini C. (2007). EBV associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil. Neuro Oncol. 9: 364–69.
[21] Oyama H., Yamao K., Sugiyama T., Matsuura O., Murakami S., Ikeda K., & Inoue S. (1997). A case of malignant lymphoma after renal transplantation. No Shinkei Geka. Neurological Surgery, 25 (7): 655-60.
[22] Phan T. G., O’Neill B. P., & Kurtin P. J. (2000). Posttransplant primary CNS lymphoma. Neuro Oncol 2: 229–238.
[23] Ponticelli C. (2011). Herpes Viruses and Tumors in Kidney Transplant Recipients. The Role of Immunosuppression. Nephrol Dial Transplant. 26 (6): 1769-75.
[24] Rezk S. A., & Weiss L. M. (2006). Epstein-Barr virus-associated diseases. Annu Rev Pathol Mech Dis 38: 375–404.
[25] Snanoudj R., Durrbach A., Leblond V., Caillard S., Hurault De Ligny B., Noel C., Rondeau E., Moulin B., Mamzer-Bruneel M. F., Lacroix C., & Charpentie B. (2003). Primary Brain Lymphomas after Kidney Transplantation: Presentation and Outcome. Transplantation, 27; 76 (6): 930-7.
[26] Sola-Valls N., Rodrıguez N. Y., Arcal C., Duran C., Oppenheimer F., Ribalta T., Lopez-Guillermo A., Campistol J. M., Graus F., & Diekmann F. (2014). Primary brain lymphomas after kidney transplantation: an under-recognized problem? J Nephrol 27: 95–102.
[27] Tedesco-Silva H., Rial M. D. C., Santiago J. C., Mazzali M., Pacheco-Silva A., & Torres A. R. (2019) Optimizing the clinical utility of sirolimus-based immunosuppression for kidney transplantation, Clin. Transplant. 33 e13464.
[28] Vaglio A., Manenti L., Mancini C., Chierici E., Cobelli R., Bacci F., Palmisano A., Buzio C., Bignardi L., & Maggiore U. (2010). EBV-Associated Leukoencephalopathy with Late Onset of Central Nervous System Lymphoma in a Kidney Transplant Recipient. American Journal of Transplantation 10: 947–951.
[29] Valavoor S. H., Ashraf Z., Narwal R., & Ratnam S. (2013). Conservative management of post-transplant central nervous system lymphoma. Int Urol Nephrol 45: 1219–1222.
[30] Velvet A. J. J., Bhutani S., Christos S. P., Dwivedi R., Picton M., Augustine T., & Morton M. (2019). A single-center experience of post-transplant lymphomas involving the central nervous system with a review of current literature. Oncotarget, Vol. 10, (No. 4), pp: 437-448.
[31] Yaginuma T., Yamamoto H., Mitome J., Tanno Y., Yamamoto I., Kobayashi A., Mafune A., Hayakawa H., Yokoyama K., Mori R., Ohashi H., Kaito N., Joki T., Miki J., Yamada H., Furuta N., Matsushima S., Fukuda T., & Hosoya T. (2012). Successful treatment of monomorphic primary central nervous system post-transplantation lymphoproliferative disorder 5 years after kidney transplantation. Transpl Infect Dis. 14 (5): E102-6.
Cite This Article
  • APA Style

    Isabella Opoku, Lin Qin Tang, Lidan Jiang, Dan Dan Wang, Xu Yueqiao, et al. (2021). Late Primary B Cell Cerebral Lymphoma After Kidney Transplant: A Case Report and Literature Review. Journal of Surgery, 9(4), 193-198. https://doi.org/10.11648/j.js.20210904.19

    Copy | Download

    ACS Style

    Isabella Opoku; Lin Qin Tang; Lidan Jiang; Dan Dan Wang; Xu Yueqiao, et al. Late Primary B Cell Cerebral Lymphoma After Kidney Transplant: A Case Report and Literature Review. J. Surg. 2021, 9(4), 193-198. doi: 10.11648/j.js.20210904.19

    Copy | Download

    AMA Style

    Isabella Opoku, Lin Qin Tang, Lidan Jiang, Dan Dan Wang, Xu Yueqiao, et al. Late Primary B Cell Cerebral Lymphoma After Kidney Transplant: A Case Report and Literature Review. J Surg. 2021;9(4):193-198. doi: 10.11648/j.js.20210904.19

    Copy | Download

  • @article{10.11648/j.js.20210904.19,
      author = {Isabella Opoku and Lin Qin Tang and Lidan Jiang and Dan Dan Wang and Xu Yueqiao and Ling Feng and Wang Ning},
      title = {Late Primary B Cell Cerebral Lymphoma After Kidney Transplant: A Case Report and Literature Review},
      journal = {Journal of Surgery},
      volume = {9},
      number = {4},
      pages = {193-198},
      doi = {10.11648/j.js.20210904.19},
      url = {https://doi.org/10.11648/j.js.20210904.19},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.js.20210904.19},
      abstract = {Background: Primary central nervous system post-transplant lymphoproliferative disorder (PCNS-PTLD) is a serious and uncommon complication which can be developed months or years after a Kidney transplant. Immunosuppressive agents administered before and after transplantation to minimize the chances of allograft rejection has proved to be a double-edged sword that puts the host at risk of infectious, neoplastic and vascular diseases, including PCNS-PTLD. The immunosuppressive therapy leads to decreased innate malignant and viral immune surveillance and this has been shown to play a role in lymphoproliferative diseases after transplantation. In most cases, PCNS-PTLD is Epstein–Barr virus related. Case Description: A 60-year-old female with history of kidney transplant presented to the emergency room with history of low fever, dizziness nausea and vomiting for 1 month. MRI and CT scans showed a mass cerebellar lesion and a biopsy revealed Primary central nervous system post-transplant lymphoproliferative disorder (PCNS-PTLD). Conclusion: This case highlights the need for a careful long-term follow up of patients with kidney transplant. PCNS-PTLD represents a continuing long-term risk after transplantation, although less common. This case report supports observational data that suggests that peripheral blood screening for EBV DNA does not seem helpful for identification of PCNS-PTLD. Suspicion of PCNS PTLD should be considered when patients with long-term history of kidney transplant present neurological complaints.},
     year = {2021}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Late Primary B Cell Cerebral Lymphoma After Kidney Transplant: A Case Report and Literature Review
    AU  - Isabella Opoku
    AU  - Lin Qin Tang
    AU  - Lidan Jiang
    AU  - Dan Dan Wang
    AU  - Xu Yueqiao
    AU  - Ling Feng
    AU  - Wang Ning
    Y1  - 2021/08/02
    PY  - 2021
    N1  - https://doi.org/10.11648/j.js.20210904.19
    DO  - 10.11648/j.js.20210904.19
    T2  - Journal of Surgery
    JF  - Journal of Surgery
    JO  - Journal of Surgery
    SP  - 193
    EP  - 198
    PB  - Science Publishing Group
    SN  - 2330-0930
    UR  - https://doi.org/10.11648/j.js.20210904.19
    AB  - Background: Primary central nervous system post-transplant lymphoproliferative disorder (PCNS-PTLD) is a serious and uncommon complication which can be developed months or years after a Kidney transplant. Immunosuppressive agents administered before and after transplantation to minimize the chances of allograft rejection has proved to be a double-edged sword that puts the host at risk of infectious, neoplastic and vascular diseases, including PCNS-PTLD. The immunosuppressive therapy leads to decreased innate malignant and viral immune surveillance and this has been shown to play a role in lymphoproliferative diseases after transplantation. In most cases, PCNS-PTLD is Epstein–Barr virus related. Case Description: A 60-year-old female with history of kidney transplant presented to the emergency room with history of low fever, dizziness nausea and vomiting for 1 month. MRI and CT scans showed a mass cerebellar lesion and a biopsy revealed Primary central nervous system post-transplant lymphoproliferative disorder (PCNS-PTLD). Conclusion: This case highlights the need for a careful long-term follow up of patients with kidney transplant. PCNS-PTLD represents a continuing long-term risk after transplantation, although less common. This case report supports observational data that suggests that peripheral blood screening for EBV DNA does not seem helpful for identification of PCNS-PTLD. Suspicion of PCNS PTLD should be considered when patients with long-term history of kidney transplant present neurological complaints.
    VL  - 9
    IS  - 4
    ER  - 

    Copy | Download

Author Information
  • Department of Neurosurgery, China International Neuroscience Institute (China-INI), Xuanwu Hospital- Capital Medical University, Beijing, China

  • Department of Neurosurgery, China International Neuroscience Institute (China-INI), Xuanwu Hospital- Capital Medical University, Beijing, China

  • Department of Neurosurgery, China International Neuroscience Institute (China-INI), Xuanwu Hospital- Capital Medical University, Beijing, China

  • Department of Pathology, China International Neuroscience Institute (China-INI), Xuanwu Hospital - Capital Medical University, Beijing, China

  • Department of Neurosurgery, China International Neuroscience Institute (China-INI), Xuanwu Hospital- Capital Medical University, Beijing, China

  • Department of Neurosurgery, China International Neuroscience Institute (China-INI), Xuanwu Hospital- Capital Medical University, Beijing, China

  • Department of Neurosurgery, China International Neuroscience Institute (China-INI), Xuanwu Hospital- Capital Medical University, Beijing, China

  • Sections